Aurobindo Pharma · Analyst questions, management answers, and the quality of the response where the ledger is available.
ConCallIQ research layer
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Questions audited
12
Answered directly
63%
Numeric claims
3
Consistency
contradicted
Question ledger
Kunal Randeria · Research desk
evasiveKunal, you're absolutely right. But if you recollect in the last earnings call, I said very clearly we will revisit the EBITDA guidance in the earnings call of November, that is the second quarter call. We will be looking into that and then reply accordingly.
Amey Chalke · JM Financial
evasiveWe are not specifically talking about revenue as a separate sales segment, but our run rate continues to be in a similar way when we launch the product, and we expect to continue in a similar way.
Neha Manpuria · Research desk
directYes, you're right. In fact, we thought last year, Q4, we have taken the hit, but because we wanted to be robust enough in terms of our remediation action, so it continued in Q1 as well. So our overall manufacturing was not to the fullest extent what it used to be. So Q4 and Q1, two quarters, I have taken the hit in terms of other remediation actions for the Eugia Unit III plant. So I'm cautiously optimistic that from this quarter onwards, that is Q2 of FY25 onwards, our regular injectable business should move up.
Damayanti Kerai · Research desk
directWe have in Q1, we have spent around $9 million against the remediation cost of Eugia Unit 3, and we expect Q2 to be only a very fraction of that $9 million. I think hopefully it'll be around $2 million, and we have completed all the remediation, and we don't expect anything more than what we have already spent.
Shyam Srinivasan · Research desk
directI think, Shyam, in terms of the Europe business, I think they have been doing it extremely well in the last 2-3 quarters. They have been gradually increasing their overall revenue, overall margins, and I think the margins have already moved to nearly mid-teens level. And with the way Murali has communicated, and this is expected to be sustained, if not improved.
Bino · Research desk
directDeflazacort, yes, we launched this product. At this point, I think we are the only player.
Jigar Valia · Research desk
partialSo, Mr. Jigar, last year, I think if I'm right, in the month of August, the board has decided to evaluate, explore various options. And we put it on hold subsequently because the inspection for the Eugia business has started. All the units have got the inspection. So now that inspections are over, we can revisit it. And some of the bankers are also approaching us. So we have to decide. But as a non-executive decision taken, and we are going to implement, we will certainly inform the market as per the compliance.
Kunal Dhamesha · Research desk
directSome of the units, like biosimilars company and the Lyfius, which is a Penicillin tech company, where we are incurring the OpEx, we are not taking the deferred tax credit. Right? Once we start a tax credit, obviously it will fall down. And in terms of the year as a whole, with a Lyfius' plan, expected to do well by fourth quarter, etc., probably we may come to a more than a break-even scenario by which the tax rate and the tax credits will be taken. The tax rate will come down. Overall, I think we will be somewhere around 27%-28% is what my feeling at this particular point of time.
Tarang Agrawal · Research desk
directRevenue impact, I told you like last quarter, that is Q4 of FY24, we had a $20 million revenue impact. And Q1, we had around similar $50 to $20 million impact. Okay. And we hope that's the end of it.
Tarang Agrawal · Research desk
evasiveI will not give a specific number, but I can generally talk about it. The U.S. business, as you have seen, has been doing well. We have made major strides in building on our past success. ... We are also expecting commercialization sometime in the near future for the US oral solid. So overall, I feel fairly optimistic, and we believe that the US oral solid will do well. As far as the number is concerned, we had a good amount of growth in the recent past. And if this continues, we should be close to that number or achieve that number sometime soon.
Tarang Agrawal · Research desk
directRyzneuta, unfortunately, there were some problems with the CMO. We were due to launch in the Q2 of this year. The problems are being resolved, and I think there could be a delay, and the launch would be probably in the last quarter of the current fiscal at this point of time.
Bino · Research desk
evasiveBino, right now, the markets are still under discussion, but it will be a majority of the markets with probably Europe also coming in. But owing to the confidentiality nature of the discussions that are unfolding between my team and the MSD, I would not be able to provide any more update on this now.
